Disulfiram and copper combination therapy targets NPL4, cancer stem cells and extends survival in a medulloblastoma model

BACKGROUND: Medulloblastoma (MB) is the most common brain malignancy in children, and is still responsible for significant mortality and morbidity. The aim of this study was to assess the safety and efficacy of Disulfiram (DSF), an FDA-approved inhibitor of Aldehyde-Dehydrogenase (ALDH), and Copper...

Descripción completa

Detalles Bibliográficos
Autores principales: Serra, Riccardo, Zhao, Tianna, Huq, Sakibul, Gorelick, Noah Leviton, Casaos, Joshua, Cecia, Arba, Mangraviti, Antonella, Eberhart, Charles, Bai, Renyuan, Olivi, Alessandro, Brem, Henry, Jackson, Eric M., Tyler, Betty
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8565761/
https://www.ncbi.nlm.nih.gov/pubmed/34731160
http://dx.doi.org/10.1371/journal.pone.0251957

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8565761/
https://www.ncbi.nlm.nih.gov/pubmed/34731160
http://dx.doi.org/10.1371/journal.pone.0251957

Ejemplares similares